Literature DB >> 29396627

[Alvimopan for recovery of bowel function after radical cystectomy].

Jennifer Kranz1,2, Laura-Maria Krabbe3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29396627     DOI: 10.1007/s00120-018-0579-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  7 in total

1.  Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.

Authors:  Cheryl T Lee; Sam S Chang; Ashish M Kamat; Gilad Amiel; Timothy L Beard; Amr Fergany; R Jeffrey Karnes; Andrea Kurz; Venu Menon; Wade J Sexton; Joel W Slaton; Robert S Svatek; Shandra S Wilson; Lee Techner; Richard Bihrle; Gary D Steinberg; Michael Koch
Journal:  Eur Urol       Date:  2014-02-26       Impact factor: 20.096

2.  Moving Towards Widespread Implementation of Enhanced Recovery Protocols for Radical Cystectomy.

Authors:  Philip J Cheng; Mark A Preston
Journal:  Eur Urol       Date:  2016-06-24       Impact factor: 20.096

3.  Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection.

Authors:  Michael Kraft; Robert Maclaren; Wei Du; Gay Owens
Journal:  P T       Date:  2010-01

Review 4.  Alvimopan for recovery of bowel function after radical cystectomy.

Authors:  Shahnaz Sultan; Bernadette Coles; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-05-02

Review 5.  Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs.

Authors:  Raed A Azhar; Bernard Bochner; James Catto; Alvin C Goh; John Kelly; Hiten D Patel; Raj S Pruthi; George N Thalmann; Mihir Desai
Journal:  Eur Urol       Date:  2016-03-09       Impact factor: 20.096

6.  Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus.

Authors:  Goldina Ikezuagu Erowele
Journal:  P T       Date:  2008-10

7.  Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.

Authors:  Teresa L Kauf; Robert S Svatek; Gilad Amiel; Timothy L Beard; Sam S Chang; Amr Fergany; R Jeffrey Karnes; Michael Koch; Jerome O'Hara; Cheryl T Lee; Wade J Sexton; Joel W Slaton; Gary D Steinberg; Shandra S Wilson; Lee Techner; Carolyn Martin; Jessica Moreno; Ashish M Kamat
Journal:  J Urol       Date:  2013-12-14       Impact factor: 7.450

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.